BRIEF published on 04/08/2025 at 07:51, 1 day 2 hours ago GenSight Biologics Files its 2024 Universal Registration Document AMF Gene Therapy Registration Document GenSight Biologics Retina
BRIEF published on 04/08/2025 at 07:51, 1 day 2 hours ago GenSight Biologics Dépose son Document d’Enregistrement Universel 2024 AMF Thérapie Génique Document D'enregistrement GenSight Biologics Rétine
BRIEF published on 04/08/2025 at 07:48, 1 day 2 hours ago GenSight Biologics dépose son document d'enregistrement universel 2024 Document D'Enregistrement Universel GenSight Biologics Thérapies Géniques Maladies De La Rétine Rapport Financier 2024
BRIEF published on 04/08/2025 at 07:48, 1 day 2 hours ago GenSight Biologics Files 2024 Universal Registration Document Universal Registration Document GenSight Biologics Gene Therapies Retinal Diseases Financial Report 2024
PRESS RELEASE published on 04/08/2025 at 07:46, 1 day 2 hours ago INFORMATIONS PRIVILÉGIÉES / AUTRES COMMUNIQUÉS GenSight Biologics met à disposition son Document d'Enregistrement Universel 2024 pour consultation en ligne Document D'Enregistrement Universel GenSight Biologics Thérapies Géniques Maladies Neurodégénératives Rétine
PRESS RELEASE published on 04/08/2025 at 07:43, 1 day 2 hours ago INSIDE INFORMATION / OTHER NEWS RELEASES GenSight Biologics announces the filing of its 2024 Universal Registration Document with the French market authority, including financial reports and corporate governance details GenSight Biologics Gene Therapies Retinal Neurodegenerative Diseases 2024 Universal Registration Document Central Nervous System Disorders
BRIEF published on 04/07/2025 at 20:19, 1 day 13 hours ago GenSight Biologics Financial and Business Update Fundraising Clinical Trials Gene Therapy Financial Update GenSight Biologics
BRIEF published on 04/07/2025 at 20:19, 1 day 13 hours ago Mise à jour financière et commerciale de GenSight Biologics Essais Cliniques Thérapie Génique Mise À Jour Financière Collecte De Fonds GenSight Biologics
PRESS RELEASE published on 04/07/2025 at 20:14, 1 day 13 hours ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie sa situation de trésorerie au 31 mars 2025, annonce des activités de levées de fonds pour prolonger l'horizon de trésorerie et fait le point sur ses activités Trésorerie Essai Clinique GenSight Biologics Thérapies Géniques Levées De Fonds
PRESS RELEASE published on 04/07/2025 at 20:14, 1 day 13 hours ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and business update as of March 31, 2025. Discussions with French agency progressing. Fundraising planned for Phase III trial and marketing advancement Business Update Cash Position Fundraising Activities GenSight Biologics RECOVER Phase III Trial
Published on 04/09/2025 at 09:00, 56 minutes ago Touchstone Exploration Announces Changes to Its Board of Directors
Published on 04/09/2025 at 08:00, 1 hour 56 minutes ago Ondine Biomedical Inc. - Economic Study Suggests c.£200 Million UK Savings
Published on 04/09/2025 at 07:40, 2 hours 16 minutes ago RTG Mining Inc. Announces Issue Of A$4.2 million Chess Depository Instruments Under Placement
Published on 04/09/2025 at 04:00, 5 hours 56 minutes ago QNX Now Powering WeRide's Next-Generation ADAS Platform
Published on 04/08/2025 at 22:47, 11 hours 9 minutes ago MicroVision Announces Retail Investor Day in Redmond, WA on May 20, 2025
Published on 04/09/2025 at 09:37, 18 minutes ago Partec AG: ParTec AG announces major participation in advancing Europe’s Digital Autonomy in HPC and AI with the DARE SGA1 Project
Published on 04/09/2025 at 09:24, 31 minutes ago H&R GmbH & Co. KGaA publishes Annual Report and Sustainability Report for FY 2024
Published on 04/09/2025 at 09:06, 49 minutes ago EQS-Adhoc: swissnet Group announces delisting of its shares from Euronext Access+ Paris
Published on 04/09/2025 at 09:05, 51 minutes ago More Impact AG introduces Z-Boxx as an innovative smoking cessation product
Published on 04/09/2025 at 09:00, 55 minutes ago Original-Research: Multitude SE (von NuWays AG): BUY
Published on 04/09/2025 at 09:00, 56 minutes ago STEF : Avis de mise à disposition des comptes annuels 2024
Published on 04/09/2025 at 08:00, 1 hour 56 minutes ago Museum Studio becomes a majority shareholder in Lord Cultural Resources
Published on 04/09/2025 at 08:00, 1 hour 56 minutes ago Museum Studio devient actionnaire majoritaire de Lord Cultural Resources
Published on 04/09/2025 at 07:00, 2 hours 56 minutes ago Biophytis confirme le lancement de l’essai clinique de Phase 2 OBA dans l’obésité
Published on 04/09/2025 at 07:00, 2 hours 56 minutes ago Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
